MeiraGTx公布AAV-hAQP1治疗2/3级晚期放射性口干症一期Aquax临床研究三年积极数据

美股速递
Apr 16

生物技术公司MeiraGTx Holdings Plc近日宣布,其针对2/3级晚期放射性口干症开发的基因疗法AAV-hAQP1,在一期Aquax临床研究中展现出长达三年的持续积极疗效。该研究数据证实了该疗法在改善患者唾液分泌功能方面的持久性与安全性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10